Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Aprea Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aprea Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$13.20M. For fiscal 2025 it was -$13.21M. The highest annual figure on record is -$13.21M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.21M | – |
| FY2024 | Dec 31, 2024 | -$14.30M | – |
| FY2023 | Dec 31, 2023 | -$15.46M | – |
| FY2022 | Dec 31, 2022 | -$113.39M | – |
| FY2021 | Dec 31, 2021 | -$37.43M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$98.46M | – |
See a number that looks wrong?